BVS857 ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
1球脊髄性筋萎縮症4

1. 球脊髄性筋萎縮症


臨床試験数 : 18 薬物数 : 15 - (DrugBank : 8) / 標的遺伝子数 : 10 - 標的パスウェイ数 : 17
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2013-002608-15-DE
(EUCTR)
15/08/201415/04/2014A study of the safety and effectiveness of BVS857 in spinal and bulbar muscular atrophyA two-part placebo-controlled study to evaluate the safety, tolerability andpreliminary efficacy of BVS857 in patients with spinal and bulbar muscularatrophy (SBMA) Spinal and bulbar muscular atrophy (SBMA)
MedDRA version: 18.1;Level: PT;Classification code 10068597;Term: Bulbospinal muscular atrophy congenital;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Product Code: BVS857
INN or Proposed INN: -
Novartis Pharma Services AGNULLNot RecruitingFemale: no
Male: yes
38Phase 2United States;Denmark;Germany;Italy
2EUCTR2013-002608-15-IT
(EUCTR)
12/06/201414/02/2014A study of the safety and effectiveness of BVS857 in spinal and bulbar muscular atrophyA two-part placebo-controlled study to evaluate the safety, tolerability andpreliminary efficacy of BVS857 in patients with spinal and bulbar muscularatrophy (SBMA) Spinal and bulbar muscular atrophy (SBMA)
MedDRA version: 16.1;Level: PT;Classification code 10068597;Term: Bulbospinal muscular atrophy congenital;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Product Code: BVS857
INN or Proposed INN: NA
Other descriptive name: NA
Novartis Farma SpANULLNot RecruitingFemale: no
Male: yes
38Phase 2United States;Denmark;Germany;Italy
3EUCTR2013-002608-15-DK
(EUCTR)
19/05/201421/03/2014A study of the safety and effectiveness of BVS857 in spinal and bulbar muscular atrophyA two-part placebo-controlled study to evaluate the safety, tolerability and preliminary efficacy of BVS857 in patients with spinal and bulbar muscular atrophy (SBMA) Spinal and bulbar muscular atrophy (SBMA)
MedDRA version: 18.1;Level: PT;Classification code 10068597;Term: Bulbospinal muscular atrophy congenital;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Product Code: BVS857Novartis Pharma Services AGNULLNot RecruitingFemale: no
Male: yes
38Phase 2United States;Denmark;Germany;Italy
4NCT02024932
(ClinicalTrials.gov)
February 4, 201429/12/2013Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular AtrophyA Two-part Placebo-controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy (SBMA)Spinal and Bulbar Muscular AtrophyDrug: BVS857;Drug: PlaceboNovartis PharmaceuticalsNULLCompleted18 YearsN/AMale37Phase 2United States;Denmark;Germany;Italy